Post TAVI pacemaker implantation does not increase mortality

Original Title: Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement. A Systematic Review and Meta-Analysis.
Reference: Ander Regueiro et al. Circ Cardiovasc Interv. 2016 May;9(5).

 

Available data on the clinical impact of the new-onset left bundle branch block (LBBB) and the need of permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation (TAVI) remain controversial.

The aim of this meta-analyzis was, on one hand, to assess the impact of the new-onset LBBB and PPI on all-cause mortality at one year and, on the other hand, to determine the new-onset LBBB predictive value on the need of PPI.

In all, this meta-analyzis included 17 studies with 11788 patients with data on the impact of the new-onset LBBB and the need of PPI. The new-onset LBBB post TAVI was associated with a greater need of PPI (RR 2.18; CI 95%, 1.28 to 3.70) and a higher risk of cardiac death (RR 1.39; CI 95% 1.04 to 1.86) as well as a tendency to increase all-cause mortality (RR 1.21; CI 95% 0.98 to 1.50).

The need of PPI post TAVI was not associated to an increase in all-cause mortality at one year (RR 1.03; CI 95% 0.9 to 1.18). In fact, it showed a tendency to have a protective effect against cardiac death (RR 0.78; CI 95% 0.60–1.03).

Conclusion
The new-onset left bundle branch block post TAVI is a risk marker of cardiac death and need of PPI at one year follow up. The need of PPI immediately post implantation, was not associated with an increase in mortality.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...